Pathophysiology of thrombotic thrombocytopenic purpura

Blood

Volumn 130, Issue 10, 2017, Pages 1181-1188

  Sadler, J Evan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ANTIBODY; HIGH DENSITY LIPOPROTEIN; PROTEINASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN;

DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOTIC THROMBOCYTOPENIC PURPURA; DEFICIENCY; METABOLISM; PATHOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE;

ADAM PROTEINS; HUMANS; PLATELET ADHESIVENESS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 85029209307     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-04-636431     Document Type: Review

References (97)

1. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2): 139-159.
2. Rock GA, Shumak KH, Buskard NA, et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393-397.
3. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307(23):1432-1435.
4. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA. 2007;104(19):7899-7903.
5. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci USA. 2002;99(1):425-430.
6. Ulrichts H, Vanhoorelbeke K, Girma JP, Lenting PJ, Vauterin S, Deckmyn H. The von Willebrand factor self-association is modulated by a multiple domain interaction. J Thromb Haemost. 2005; 3(3):552-561.
7. Zhang X, Halvorsen K, Zhang C-Z, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334.
8. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100(12):4033-4039.
9. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood. 2008;111(2):651-657.
10. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem. 2010;285(37): 28596-28603.
11. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977.
12. Casonato A, Steffan A, Pontara E, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999;81(2):224-228.
13. Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001;49(5):653-659.
14. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834-839.
15. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood. 2010;116(12):2005-2010.
16. Schmitto JD, Ortmann P, Vorkamp T, et al. Histological changes in a model of chronic heart failure induced by multiple sequential coronary microembolization in sheep [published correction appears in J Cardiovasc Surg (Torino). 2010;51 (1):143]. J Cardiovasc Surg (Torino). 2008;49(4): 533-537.
17. de Lange F, Dieleman JM, Blezer EL, Houston RJ, Kalkman CJ, Nijsen JF. Unilateral intracarotid injection of holmium microspheres to induce bilateral MRI-validated cerebral embolization in rats. J Neurosci Methods. 2009;176(2):152-156.
18. Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med. 1979;91(3):357-363.
19. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45(2):246-251.
20. Herbig BA, Diamond SL. Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation. J Thromb Haemost. 2015;13(9): 1699-1708.
21. Zheng Y, Chen J, López JA. Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun. 2015;6:7858.
22. Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood. 2012;120(17): 3611-3614.
23. Morioka Y, Casari C, Wohner N, et al. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. Blood. 2014; 123(21):3344-3353.
24. Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119(25):6128-6135.
25. Muchitsch EM, Dietrich B, Rottensteiner H, et al. Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability. Semin Thromb Hemost. 2010;36(5):522-528.
26. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
27. Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher. 2012; 27(4):221-226.
28. Htun KT, Davis AK. Neurological symptoms as the sole presentation of relapsed thrombotic thrombocytopenic purpura without microangiopathic haemolytic anaemia. Thromb Haemost. 2014;112(4):838-840.
29. Idowu M, Reddy P. Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. Am J Hematol. 2013;88(3):237-239.
30. Rojas JC, Banerjee C, Siddiqui F, Nourbakhsh B, Powell CM. Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology. 2013; 80(22):e235-e238.
31. Sevy A, Doche E, Squarcioni C, et al. Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura. J Clin Apher. 2011;26(3):152-155.
32. Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10(8):1556-1565.
33. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141(5):651-658.
34. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232-239.
35. Ferrari S, Scheiflinger F, Rieger M, et al; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7): 2815-2822.
36. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2016;128(17):2175-2178.
37. Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol. 2004;41(1): 75-82.
38. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11): 4043-4049.
39. Mansouri Taleghani M, von Krogh AS, Fujimura Y, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013;33(2):138-143.
40. Scully M, Thomas M, Underwood M, et al; collaborators of the UK TTP Registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2): 211-219.
41. Moatti-Cohen M, Garrec C, Wolf M, et al; French Reference Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888-5897.
42. Coppo P, Bengoufa D, Veyradier A, et al; Réseau d’Etude des Microangiopathies Thrombotiques de l’Adulte. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83(4):233-244.
43. Roriz M, Landais M, Desprez J, et al; French Thrombotic Microangiopathies Reference Center. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore). 2015;94(42): e1598.
44. Sorvillo N, van Haren SD, Kaijen PH, et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood. 2013; 121(17):3502-3510.
45. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761.
46. Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood. 2008; 111(7):3452-3457.
47. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost. 2004;92(4):886-887.
48. Hara T, Kitano A, Kajiwara T, Kondo T, Sakai K, Hamasaki Y. Factor VIII concentrate-responsive thrombocytopenia, hemolytic anemia, and nephropathy. Evidence that factor VIII:von Willebrand factor is involved in its pathogenesis. Am J Pediatr Hematol Oncol. 1986;8(4):324-328.
49. Veyradier A, Meyer D, Loirat C. Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost. 2006;4(3):700-701.
50. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9(suppl 1):283-301.
51. Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2): 440-448.
52. Rurali E, Banterla F, Donadelli R, et al. ADAMTS13 secretion and residual activity among patients with congenital thrombotic thrombocytopenic purpura with and without renal impairment. Clin J Am Soc Nephrol. 2015;10(11): 2002-2012.
53. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
54. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14(2):437-454.
55. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511, quiz 1662.
56. Morgand M, Buffet M, Busson M, et al; Thrombotic Microangiopathies Reference Center. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion. 2014;54(2):389-397.
57. Wang Y, Chen J, Ling M, López JA, Chung DW, Fu X. Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation. J Biol Chem. 2015;290(3): 1422-1431.
58. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115(3):706-712.
59. Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, López JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood. 2011;118(19): 5283-5291.
60. Raife TJ, Cao W, Atkinson BS, et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114(8):1666-1674.
61. Lancellotti S, De Filippis V, Pozzi N, et al. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13. J Thromb Haemost. 2011;9(8): 1620-1627.
62. Hollestelle MJ, Lai KW, van Deuren M, et al. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One. 2011;6(9):e24216.
63. Wohner N, Kovács A, Machovich R, Kolev K. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways. Thromb Res. 2012;129(4): e41-e46.
64. Tersteeg C, de Maat S, De Meyer SF, et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation. 2014; 129(12):1320-1331.
65. Brophy TM, Ward SE, McGimsey TR, et al. Plasmin cleaves von Willebrand factor at K1491-R1492 in the A1-A2 linker region in a shear- and glycan-dependent manner in vitro. Arterioscler Thromb Vasc Biol. 2017;37(5):845-855.
66. Feys HB, Vandeputte N, Palla R, et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(9): 2053-2062.
67. Chung DW, Chen J, Ling M, et al. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood. 2016; 127(5):637-645.
68. Scully M, Knoebl P, Kentouche K, Doralt J, Maggiore C, Ewenstein B. Recombinant human ADAMTS13: first-in-human study evaluating pharmacokinetics, safety and tolerability in hTTP patients [abstract]. J Thromb Haemost. 2016; 14(suppl 1):39. Abstract FIB04.
69. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9(5): 936-944.
70. Tersteeg C, Schiviz A, De Meyer SF, et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2015;35(11):2336-2342.
71. Jian C, Xiao J, Gong L, et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2012;119(16):3836-3843.
72. Pickens B, Mao Y, Li D, et al. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood. 2015;125(21):3326-3334.
73. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-1753.
74. Froissart A, Buffet M, Veyradier A, et al; French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med. 2012;40(1):104-111.
75. Hie M, Gay J, Galicier L, et al; French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2): 204-210.
76. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481-490.
77. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127(24): 3092-3094.
78. Benhamou Y, Paintaud G, Azoulay E, et al; French Reference Center for Thrombotic Microangiopathies. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. Am J Hematol. 2016;91(12):1246-1251.
79. Tong HY, Ye LI, Ye XN, Lu DM, Li Y. Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases. Exp Ther Med. 2015;10(6):2295-2298.
80. Vazquez-Mellado A, Pequeño-Luévano M, Cantu-Rodriguez OG, et al. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematology. 2016; 21(5):311-316.
81. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013; 368(1):90-92.
82. Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016;173(5):779-785.
83. Eskazan AE. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol. 2016; 95(11):1751-1756.
84. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121(2):593-603.
85. Tersteeg C, Roodt J, Van Rensburg WJ, et al. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood. 2017;129(8):1030-1038.
86. Le Behot A, Gauberti M, Martinez De Lizarrondo S, et al. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014; 123(21):3354-3363.
87. Yamashita A, Asada Y, Sugimura H, et al. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol. 2003;23(6):1105-1110.
88. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(4):430-432.
89. Oney S, Nimjee SM, Layzer J, et al. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides. 2007;17(3):265-274.
90. Wadanoli M, Sako D, Shaw GD, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost. 2007;98(2): 397-405.
91. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22(2):323-328.
92. Sixma JJ, Ijsseldijk MJ, Hindriks G, et al. Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler Thromb Vasc Biol. 1996;16(1):64-71.
93. Zheng L, Mao Y, Abdelgawwad MS, et al. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv. 2016;1(1):75-83.
94. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757-765.
95. Peyvandi F, Scully M, Kremer Hovinga JA, et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522.
96. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156-1164.
97. Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4):612-615.